{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:30:45Z","timestamp":1792798245681,"version":"4.5.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2022R1F1A1074583"],"award-info":[{"award-number":["2022R1F1A1074583"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug\u2013drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.<\/jats:p>","DOI":"10.1371\/journal.pone.0287382","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T17:23:57Z","timestamp":1686936237000},"page":"e0287382","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug\u2013Drug interactions of docetaxel in patients with breast cancer based on insurance claims data"],"prefix":"10.1371","volume":"18","author":[{"given":"Kwang-Hee","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Mi","family":"Ah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-6827","authenticated-orcid":true,"given":"Hye Duck","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"pone.0287382.ref001","unstructured":"Docetaxel (Taxotere\u00ae). Prescribing Information. https:\/\/products.sanofi.us\/taxotere\/taxotere.html. Accessed August 16, 2021."},{"key":"pone.0287382.ref002","volume-title":"NCCN Clinical practice guidelines in oncology: breast cancer.","author":"National Comprehensive Cancer Network.","year":"2022"},{"key":"pone.0287382.ref003","volume-title":"NCCN Clinical practice guidelines in oncology: non-small cell lung cancer.","author":"National Comprehensive Cancer Network.","year":"2022"},{"key":"pone.0287382.ref004","author":"National Comprehensive Cancer Network","year":"2022"},{"key":"pone.0287382.ref005","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"1","key":"pone.0287382.ref006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","article-title":"Docetaxel-related side effects and their management","volume":"13","author":"J Baker","year":"2009","journal-title":"Eur J Oncol Nurs"},{"key":"pone.0287382.ref007","first-page":"253","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"MY Ho","year":"2014","journal-title":"Cancer Manag Res"},{"key":"pone.0287382.ref008","author":"National Comprehensive Cancer Network","year":"2022"},{"key":"pone.0287382.ref009","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.","volume":"28","author":"TJ Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"pone.0287382.ref010","unstructured":"Docetaxel. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. http:\/\/online.lexi.com. Accessed August 16, 2021."},{"key":"pone.0287382.ref011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1010691218625","article-title":"Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy","volume":"19","author":"L Vigano","year":"2001","journal-title":"Invest New Drugs"},{"issue":"12","key":"pone.0287382.ref012","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality","volume":"57","author":"V Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"pone.0287382.ref013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies","volume":"40","author":"ME Charlson","year":"1987","journal-title":"Development and Validation. J Chronic Dis"},{"key":"pone.0287382.ref014","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1006\/pmed.1994.1093","article-title":"Nested case-control studies","volume":"23","author":"VL Ernster","year":"1994","journal-title":"Prev Med."},{"key":"pone.0287382.ref015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jclinepi.2013.06.001","article-title":"The z-difference can be used to measure covariate balance in matched propensity score analyses.","volume":"66","author":"O. Kuss","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"pone.0287382.ref016","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.54724\/lc.2022.e1","article-title":"Methods for testing statistical differences between groups in medical research: statistical standard and guideline of Life Cycle Committee","volume":"2","author":"SW Lee","year":"2022","journal-title":"Life Cycle"},{"key":"pone.0287382.ref017","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.54724\/lc.2022.e3","article-title":"Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle Committee","volume":"2","author":"SW Lee","year":"2022","journal-title":"Life Cycle"},{"key":"pone.0287382.ref018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"DW Hosmer","year":"2000","edition":"1"},{"issue":"10","key":"pone.0287382.ref019","doi-asserted-by":"crossref","first-page":"195","DOI":"10.21037\/atm.2016.03.36","article-title":"Residuals and regression diagnostics: focusing on logistic regression","volume":"4","author":"Z. Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"pone.0287382.ref020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2981\/08-057","article-title":"Internal Validation of predictive logistic regression models for decision-making in wildlife management.","volume":"15","author":"JA Gude","year":"2009","journal-title":"Wildl Biol"},{"issue":"48","key":"pone.0287382.ref021","doi-asserted-by":"crossref","first-page":"19313","DOI":"10.1073\/pnas.1313476110","article-title":"Revised standards for statistical evidence","volume":"110","author":"VE Johnson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"pone.0287382.ref022","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/87551225211073942","article-title":"Potential Drug Interactions Between Psychotropics and Intravenous Chemotherapeutics Used by Patients With Cancer.","volume":"38","author":"ED Turossi-Amorim","year":"2022","journal-title":"J Pharm Technol"},{"issue":"8","key":"pone.0287382.ref023","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1007\/s00520-019-05204-2","article-title":"Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study","volume":"28","author":"SH Kim","year":"2020","journal-title":"Support Care Cancer"},{"issue":"8","key":"pone.0287382.ref024","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/000313480407000808","article-title":"Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer","volume":"70","author":"NA Patel","year":"2004","journal-title":"Am Surg"},{"issue":"3","key":"pone.0287382.ref025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1345\/aph.1L432","article-title":"Evaluation of potential interaction between vinorelbine and clarithromycin","volume":"43","author":"R Yano","year":"2009","journal-title":"Ann Pharmacother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T17:24:16Z","timestamp":1686936256000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0287382"}},"subtitle":[],"editor":[{"given":"Dong Keon","family":"Yon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0287382","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}